和元生物：上半年亏损1.05亿元

Core Viewpoint - The company reported a revenue of 120 million yuan for the first half of 2025, reflecting a year-on-year growth of 6.01%, but continued to incur a net loss of 105 million yuan, although this was an improvement compared to a loss of 113 million yuan in the same period last year [1]. Financial Performance - Revenue for the first half of 2025 reached 120 million yuan, marking a 6.01% increase year-on-year [1]. - The net profit attributable to shareholders was -105 million yuan, an improvement from -113 million yuan in the previous year [1]. - Basic earnings per share were -0.163 yuan [1]. Business Operations - The company's cell and gene therapy CDMO business faced challenges due to macroeconomic changes, industry conditions, and downstream demand [1]. - The execution order prices for the CDMO business remained at a low level [1]. - The operational costs, including depreciation, energy consumption, and administrative expenses, were relatively high, contributing to the overall loss [1]. - The gross profit margin for the cell and gene therapy CDMO business remained negative [1].